ART838 synergized with the kinase inhibitor sorafenib (SOR) and the BCL2 inhibitor venetoclax (VEN) (to form a combination regimen referred to as “SAV”) both in vitro and in AML xenograft and PDX models (20). The gene discussed is BCL2; the disease is acute myeloid leukemia.